How to buy Cerus Corporation stock (CERS)

Cerus Corporation is a medical devices business based in the US. Cerus Corporation shares (CERS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.58 – a decrease of 7.6% over the previous week. Cerus Corporation employs 625 staff and has a trailing 12-month revenue of around $176.2 million.

Our top picks for where to buy Cerus Corporation stock

Buy Cerus Corporation stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Cerus Corporation stock price (NASDAQ: CERS)

Use our graph to track the performance of CERS stocks over time.

Cerus Corporation shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$1.58
52-week range	$1.38 - $2.59
50-day moving average more info button	$1.75
200-day moving average more info button	$1.90
Wall St. target price	$3.90
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.11

Is it a good time to buy Cerus Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cerus Corporation price performance over time

Historical closes compared with the close of $1.69 from 2024-12-17

1 week (2024-12-12)	-5.06%
1 month (2024-11-20)	1.81%
3 months (2024-09-19)	-7.65%
6 months (2024-06-20)	1.69

1 year (2023-12-20)	-19.91%
2 years (2022-12-20)	-55.87%
3 years (2021-12-20)	6.62
5 years (2019-12-19)	4.15

Cerus Corporation financials

Revenue TTM	$176.2 million
Gross profit TTM	$87.1 million
Return on assets TTM	-3.73%
Return on equity TTM	-38.31%
Profit margin	-11.19%
Book value	$0.29
Market Capitalization more info button	$293.4 million

TTM: trailing 12 months

Cerus Corporation share dividends

We're not expecting Cerus Corporation to pay a dividend over the next 12 months.

Cerus Corporation share price volatility

Over the last 12 months, Cerus Corporation's shares have ranged in value from as little as $1.375 up to $2.585. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cerus Corporation's is 1.2. This would suggest that Cerus Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Cerus Corporation overview

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California. .

Frequently asked questions

null
What percentage of Cerus Corporation is owned by insiders or institutions?
Currently 3.252% of Cerus Corporation shares are held by insiders and 79.217% by institutions. How many people work for Cerus Corporation?
Latest data suggests 625 work at Cerus Corporation. When does the fiscal year end for Cerus Corporation?
Cerus Corporation's fiscal year ends in December. Where is Cerus Corporation based?
Cerus Corporation's address is: 1220 Concord Avenue, Concord, CA, United States, 94520 What is Cerus Corporation's ISIN number?
Cerus Corporation's international securities identification number is: US1570851014 What is Cerus Corporation's CUSIP number?
Cerus Corporation's Committee on Uniform Securities Identification Procedures number is: 157085101